The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer

Por Di Maio, Massimo, Scagliotti, Giorgio Vittorio
Publicado no Transl Lung Cancer Res (2015)

In Reply

Por Tampellini, Marco, Ardissone, Francesco, Scagliotti, Giorgio Vittorio
Publicado em 2013

Raising the bar for enthusiasm when looking at results of randomized phase II trials—the case of sunitinib in small-cell lung cancer

Por Di Maio, Massimo, Bironzo, Paolo, Scagliotti, Giorgio Vittorio
Publicado no Transl Lung Cancer Res (2016)

Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures

Por Carnio, Simona, Novello, Silvia, Papotti, Mauro, Loiacono, Marco, Scagliotti, Giorgio Vittorio
Publicado no Transl Lung Cancer Res (2013)

Intermittent everolimus administration for malignant insulinoma

Por Baratelli, Chiara, Brizzi, Maria Pia, Tampellini, Marco, Scagliotti, Giorgio Vittorio, Priola, Adriano, Terzolo, Massimo, Pia, Anna, Berruti, Alfredo
Publicado em 2014

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment

Por Iuliani, Michele, Pantano, Francesco, Buttigliero, Consuelo, Fioramonti, Marco, Bertaglia, Valentina, Vincenzi, Bruno, Zoccoli, Alice, Ribelli, Giulia, Tucci, Marcello, Vignani, Francesca, Berruti, Alfredo, Scagliotti, Giorgio Vittorio, Tonini, Giuseppe, Santini, Daniele
Publicado no Oncotarget (2015)